Assembly Biosciences Inc (ASMB) Expected to Announce Quarterly Sales of $1.68 Million

Analysts expect Assembly Biosciences Inc (NASDAQ:ASMB) to report sales of $1.68 million for the current quarter, Zacks Investment Research reports. Two analysts have issued estimates for Assembly Biosciences’ earnings, with estimates ranging from $700,000.00 to $2.66 million. The company is expected to report its next earnings report on Thursday, March 1st.

According to Zacks, analysts expect that Assembly Biosciences will report full-year sales of $1.68 million for the current year, with estimates ranging from $4.40 million to $8.36 million. For the next financial year, analysts expect that the firm will report sales of $3.82 million per share, with estimates ranging from $2.80 million to $4.83 million. Zacks’ sales averages are a mean average based on a survey of sell-side research analysts that follow Assembly Biosciences.

ASMB has been the topic of several recent research reports. Zacks Investment Research raised shares of Assembly Biosciences from a “hold” rating to a “buy” rating and set a $37.00 target price on the stock in a report on Wednesday, November 15th. Jefferies Group initiated coverage on shares of Assembly Biosciences in a report on Wednesday, November 8th. They set a “buy” rating and a $50.00 target price on the stock. BidaskClub cut shares of Assembly Biosciences from a “strong-buy” rating to a “buy” rating in a report on Wednesday, December 6th. Chardan Capital reaffirmed a “buy” rating on shares of Assembly Biosciences in a report on Sunday, September 17th. Finally, B. Riley initiated coverage on shares of Assembly Biosciences in a report on Friday. They set a “neutral” rating and a $35.00 target price on the stock. One analyst has rated the stock with a sell rating, two have issued a hold rating and three have given a buy rating to the company. Assembly Biosciences presently has a consensus rating of “Hold” and an average price target of $39.25.

Shares of Assembly Biosciences (NASDAQ:ASMB) traded down $1.42 on Tuesday, hitting $41.70. 125,600 shares of the stock traded hands, compared to its average volume of 113,720. Assembly Biosciences has a 12 month low of $12.15 and a 12 month high of $52.37. The company has a market capitalization of $868.04, a PE ratio of -14.04 and a beta of 0.91.

In related news, Director William R. Ringo sold 1,000 shares of the stock in a transaction that occurred on Wednesday, November 1st. The shares were sold at an average price of $29.55, for a total transaction of $29,550.00. The transaction was disclosed in a document filed with the SEC, which is accessible through this link. Insiders have sold a total of 4,000 shares of company stock worth $157,660 in the last quarter. 19.60% of the stock is currently owned by company insiders.

Several hedge funds and other institutional investors have recently bought and sold shares of ASMB. Nationwide Fund Advisors acquired a new stake in shares of Assembly Biosciences during the 2nd quarter worth approximately $161,000. Parametric Portfolio Associates LLC boosted its position in shares of Assembly Biosciences by 13.6% during the 2nd quarter. Parametric Portfolio Associates LLC now owns 10,078 shares of the biopharmaceutical company’s stock worth $208,000 after acquiring an additional 1,203 shares in the last quarter. Legal & General Group Plc acquired a new stake in shares of Assembly Biosciences during the 2nd quarter worth approximately $212,000. Wells Fargo & Company MN acquired a new stake in shares of Assembly Biosciences during the 2nd quarter worth approximately $213,000. Finally, State of Wisconsin Investment Board acquired a new stake in shares of Assembly Biosciences during the 2nd quarter worth approximately $227,000. Institutional investors and hedge funds own 61.41% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This article was first posted by Community Financial News and is owned by of Community Financial News. If you are accessing this article on another website, it was illegally stolen and reposted in violation of United States and international copyright and trademark law. The correct version of this article can be accessed at https://www.com-unik.info/2018/01/09/assembly-biosciences-inc-asmb-expected-to-announce-quarterly-sales-of-1-68-million.html.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a biotechnology company. The Company is engaged in developing two platform programs, such as a class of oral therapeutics for the treatment of hepatitis B virus (HBV) infection, and a class of oral synthetic live therapeutics, which are designed to restore health to a dysbiotic microbiome.

Get a free copy of the Zacks research report on Assembly Biosciences (ASMB)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Assembly Biosciences (NASDAQ:ASMB)

What are top analysts saying about Assembly Biosciences? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Assembly Biosciences and related companies.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit